Stifel Nicolaus Increases Edwards Lifesciences (NYSE:EW) Price Target to $83.00

Edwards Lifesciences (NYSE:EWFree Report) had its target price lifted by Stifel Nicolaus from $70.00 to $83.00 in a research note released on Wednesday morning, Benzinga reports. They currently have a hold rating on the medical research company’s stock.

A number of other research analysts have also recently commented on EW. Citigroup cut shares of Edwards Lifesciences from a buy rating to a neutral rating in a research report on Monday, December 11th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $80.00 to $95.00 and gave the stock an overweight rating in a research note on Wednesday. Piper Sandler cut their price target on shares of Edwards Lifesciences from $83.00 to $68.00 and set a neutral rating on the stock in a research note on Thursday, October 26th. Mizuho upped their target price on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the stock a buy rating in a research note on Wednesday. Finally, Leerink Partnrs restated a market perform rating on shares of Edwards Lifesciences in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of Hold and a consensus price target of $87.38.

Get Our Latest Stock Analysis on EW

Edwards Lifesciences Trading Down 0.9 %

Shares of EW stock opened at $85.01 on Wednesday. The company’s 50-day moving average price is $75.71 and its 200-day moving average price is $73.47. The company has a current ratio of 3.38, a quick ratio of 2.45 and a debt-to-equity ratio of 0.09. The stock has a market cap of $51.56 billion, a price-to-earnings ratio of 36.96, a PEG ratio of 4.31 and a beta of 1.04. Edwards Lifesciences has a twelve month low of $60.57 and a twelve month high of $94.87.

Edwards Lifesciences (NYSE:EWGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the previous year, the company posted $0.64 EPS. The company’s revenue was up 13.3% compared to the same quarter last year. As a group, equities analysts predict that Edwards Lifesciences will post 2.75 earnings per share for the current year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 6,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.30, for a total transaction of $391,800.00. Following the completion of the sale, the vice president now owns 39,503 shares in the company, valued at approximately $2,579,545.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $74.62, for a total value of $2,190,097.00. Following the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $334,745.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.30, for a total value of $391,800.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares in the company, valued at $2,579,545.90. The disclosure for this sale can be found here. Insiders sold a total of 139,339 shares of company stock worth $10,324,578 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of EW. Advisors Asset Management Inc. grew its holdings in shares of Edwards Lifesciences by 0.3% during the first quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock worth $5,127,000 after purchasing an additional 117 shares during the last quarter. Apollon Wealth Management LLC grew its holdings in shares of Edwards Lifesciences by 1.0% during the first quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock worth $1,033,000 after purchasing an additional 119 shares during the last quarter. Geller Advisors LLC grew its holdings in shares of Edwards Lifesciences by 6.5% during the first quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock worth $231,000 after purchasing an additional 120 shares during the last quarter. Private Trust Co. NA grew its holdings in shares of Edwards Lifesciences by 1.1% during the second quarter. Private Trust Co. NA now owns 11,410 shares of the medical research company’s stock worth $1,076,000 after purchasing an additional 125 shares during the last quarter. Finally, Martin Capital Advisors LLP boosted its holdings in Edwards Lifesciences by 0.5% in the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after acquiring an additional 128 shares during the last quarter. 79.25% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Recommended Stories

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.